Charles Greg Guyer
Known title: EVP, Chief Technical OfficerCIK: 0001811096
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 1,693 | $95K | 3/17/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 14,990 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 9,109 | $533K | 3/13/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 16,486 | $997K | 3/11/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 6,176 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 6,675 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 2,371 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 13,310 | $0 | 3/17/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 20,127 | $1.4M | 3/14/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 7,034 | $501K | 3/6/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,287 | $305K | 2/28/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,367 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,660 | $0 | 2/25/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,278 | $350K | 11/12/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 55 | $3K | 10/31/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,440 | $366K | 5/3/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 245 | $17K | 4/30/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 10,550 | $0 | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 20,424 | $1.7M | 3/15/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 6,284 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 20,840 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 9,063 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 11,840 | $0 | 12/1/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 133 | $9K | 10/31/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,360 | $500K | 8/9/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,302 | $411K | 5/4/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 239 | $16K | 4/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 8,900 | $0 | 3/15/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,856 | $163K | 3/15/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 6,205 | $599K | 8/8/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 3,926 | $332K | 5/4/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 243 | $15K | 4/29/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 920 | $72K | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 3/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.